The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome

Detalhes bibliográficos
Autor(a) principal: Kiaco, Kinanga
Data de Publicação: 2017
Outros Autores: Rodrigues, António Sebastião, do Rosário, Virgílio, Gil, José Pedro, Lopes, Dinora
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/36450
Resumo: Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individual performance.
id RCAP_89e54eab3c7318731a9c6426566c2ec3
oai_identifier_str oai:run.unl.pt:10362/36450
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcomeAngolaArtemether-lumefantrineCYP450Human polymorphismMDR1SDG 3 - Good Health and Well-beingMalaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individual performance.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Centre for Toxicogenomics and Human Health (ToxOmics)Instituto de Higiene e Medicina Tropical (IHMT)Global Health and Tropical Medicine (GHTM)Vector borne diseases and pathogens (VBD)RUNKiaco, KinangaRodrigues, António Sebastiãodo Rosário, VirgílioGil, José PedroLopes, Dinora2018-05-10T22:15:00Z2017-09-212017-09-21T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article6application/pdfhttp://hdl.handle.net/10362/36450engPURE: 3180599https://doi.org/10.1186/s12936-017-2006-6info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T17:32:27Zoai:run.unl.pt:10362/36450Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T17:32:27Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome
title The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome
spellingShingle The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome
Kiaco, Kinanga
Angola
Artemether-lumefantrine
CYP450
Human polymorphism
MDR1
SDG 3 - Good Health and Well-being
title_short The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome
title_full The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome
title_fullStr The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome
title_full_unstemmed The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome
title_sort The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome
author Kiaco, Kinanga
author_facet Kiaco, Kinanga
Rodrigues, António Sebastião
do Rosário, Virgílio
Gil, José Pedro
Lopes, Dinora
author_role author
author2 Rodrigues, António Sebastião
do Rosário, Virgílio
Gil, José Pedro
Lopes, Dinora
author2_role author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Centre for Toxicogenomics and Human Health (ToxOmics)
Instituto de Higiene e Medicina Tropical (IHMT)
Global Health and Tropical Medicine (GHTM)
Vector borne diseases and pathogens (VBD)
RUN
dc.contributor.author.fl_str_mv Kiaco, Kinanga
Rodrigues, António Sebastião
do Rosário, Virgílio
Gil, José Pedro
Lopes, Dinora
dc.subject.por.fl_str_mv Angola
Artemether-lumefantrine
CYP450
Human polymorphism
MDR1
SDG 3 - Good Health and Well-being
topic Angola
Artemether-lumefantrine
CYP450
Human polymorphism
MDR1
SDG 3 - Good Health and Well-being
description Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individual performance.
publishDate 2017
dc.date.none.fl_str_mv 2017-09-21
2017-09-21T00:00:00Z
2018-05-10T22:15:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/36450
url http://hdl.handle.net/10362/36450
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv PURE: 3180599
https://doi.org/10.1186/s12936-017-2006-6
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 6
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817545637009293312

Registros relacionados